UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (972) 277-1136 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common Stock | | | Name of each excha ...

| --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | Lantern Pharma | | | | | Company Overview September 13, 2021 | | | | | Leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development | | | | | Nasdaq: LTRN | | | | 1 LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking sta ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2021 Earnings Conference Call July 29, 2021 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - CFO Kishor Bhatia - CSO Conference Call Participants Kyle Bauser - Colliers Securities John Vandermosten - Zacks SCR Operator Good afternoon and welcome to Lantern Pharma’s Second Quarter 2021 Conference Call. As a reminder, this call is being recorded and all participants are in listen-only mode. We will open the call for questions-and-answers af ...

| --- | --- | |------------------------------------------------|-------| | | | | | | | Second Quarter 2021 | | | Operating & Financial Results Conference Call | | July 29, 2021 4:30 PM Eastern https://ir.lanternpharma.com/ LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other thin ...

FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Emplo ...

Lantern | --- | --- | |-------|-------| | | | | | | | | | May 3, 2021 4:30 PM Eastern https://ir.lanternpharma.com/ LTRN FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of ...

Financial Data and Key Metrics Changes - For Q1 2021, the company reported a net loss of approximately $2.45 million or $0.24 per share, compared to a net loss of approximately $477,000 or $0.24 per share for Q1 2020 [51] - Research and development expenses increased to approximately $1.3 million in Q1 2021 from $137,000 in Q1 2020, primarily due to increased research studies and team expansion [52] - General and administrative expenses rose to approximately $1.2 million in Q1 2021 from approximately $340,000 in Q1 2020, attributed to costs associated with operating as a public company [53] - The cash position as of March 31, 2021, was $81.4 million, bolstered by a $69 million follow-on public offering in January, extending the cash runway through mid-2025 [56] Business Line Data and Key Metrics Changes - The RADR AI platform surpassed 4.6 billion data points by the end of April 2021, representing a 16-fold increase since May 2020 and nearly four-fold growth since the beginning of 2021 [11][17] - The company initiated pre-clinical development of LP-284, a new molecule targeting hematologic cancers, which has shown exceptional sensitivity [12] Market Data and Key Metrics Changes - The LP-300 drug candidate targets a growing but unaddressed type of non-small cell lung cancer among non-smokers, which accounts for approximately 20% of new non-small cell lung cancer cases globally, with an estimated annual spending of $2.5 billion on therapies for this patient population [29] Company Strategy and Development Direction - The company aims to leverage its RADR AI platform to transform oncology drug development by reducing the pace, cost, and risk associated with bringing therapies to market [9][23] - The collaboration with Actuate Therapeutics is expected to enhance the development of their drug candidate using the RADR platform, potentially generating novel intellectual property [21][22] - The company is focused on expanding its pipeline of oncology drug candidates, including the development of an antibody drug conjugate program expected to enter clinical trials in 2022 [65] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering a new era of drug discovery, emphasizing the importance of AI and data-driven approaches in accelerating drug development [24][66] - The company anticipates significant opportunities for R&D collaborations and aims to establish itself as a leader in AI-driven oncology drug discovery [68][69] Other Important Information - The company has filed over 10 patent applications to strengthen its intellectual property portfolio, covering various aspects of its RADR platform and drug candidates [13] - The company has a disciplined approach to acquiring new drug assets, utilizing an internal database to evaluate oncology trials and prioritize potential candidates [94][95] Q&A Session Summary Question: What is behind the exponential growth of data points? - The growth is attributed to team expansion, improved resources, and a focus on automation to enhance data collection and management [75][76] Question: Can you clarify the relationship between LP-184 and LP-284? - LP-284 is a stereoisomer of LP-184, with distinct properties and potential effectiveness in hematologic cancers [78][79] Question: What is the cash position and appetite for acquisitions? - The company has $81.4 million in cash, with plans to grow R&D expenses while remaining open to acquiring new candidates [91][92] Question: Can you provide details on the LP-300 trial and potential partnerships? - The LP-300 trial will focus on never smoker lung adenocarcinoma patients, with plans to explore partnerships with larger pharmaceutical companies as the trial progresses [99][101] Question: Will there be cash milestones or royalty payments from collaborations? - The company plans to focus on developing high-value oncology therapies with partners, potentially involving equity or deferred cash based on success [113][115]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification No.) | | 1920 McKinney Avenue, 7th Floor | | | Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Mar ...

| --- | --- | --- | |-------------------------------------------------------------------------|-------|-------| | Lantern Pharma Company Overview April 6, 2021 | | | | Leveraging A.I., Machine Learning & Genomics to Rescue, Reposition and | | | | Develop Targeted Cancer Therapies | | | FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. ...

Financial Data and Key Metrics Changes - For Q4 2020, the company reported a net loss of $2.9 million, or $0.47 per share, compared to a net loss of $675,000, or $0.34 per share, for Q4 2019 [58] - For the full year 2020, the net loss was $5.9 million, or $1.37 per share, compared to a net loss of $2.4 million, or $1.23 per share, for 2019 [61] - Research and development expenses increased by 135% from $953,000 in 2019 to $2.2 million in 2020 [62] - General and administrative expenses rose by 149% from $1.5 million in 2019 to $3.7 million in 2020 [63] - As of December 31, 2020, the company had working capital of approximately $19.7 million, primarily due to the net proceeds from its IPO [61] Business Line Data and Key Metrics Changes - The company has increased the number of active development programs from three to seven since its IPO in June 2020 [27][18] - The RADR AI platform surpassed 1.1 billion data points by the end of 2020, with plans to reach 3 billion in 2021 [14] Market Data and Key Metrics Changes - The global antibody-drug conjugate (ADC) cancer therapy market is expected to exceed $10 billion by 2026 and $15 billion by 2030 [52] Company Strategy and Development Direction - The company aims to leverage its RADR AI platform to accelerate drug development and reduce costs associated with oncology therapies [22][72] - The focus is on building a portfolio of high-value oncology drug candidates that can be partnered for pivotal registration trials or licensed out [72] - The company is pursuing partnerships with biopharma companies to enhance the development of their programs using the RADR platform [17] Management's Comments on Operating Environment and Future Outlook - Management believes that the current era represents a "golden age" of artificial intelligence in drug development, which will significantly impact the industry [21][73] - The company is confident that its AI-driven approach can save millions in drug development costs while accelerating the path to commercialization [33] Other Important Information - The company closed a $69 million follow-on public offering in January 2021, extending its cash runway through mid-2025 [65] - The company has initiated collaborations with leading cancer research institutions, including Johns Hopkins and Georgetown University, to advance its drug candidates [28][38] Q&A Session Summary Question: How should the quarterly burn be viewed with recent updates on the ADC program and ATRT? - Management indicated that the quarterly burn will increase substantially as they move towards launching LP-300 and starting additional clinical trials for LP-184 and the ADC program [81][82] Question: Regarding the ATRT opportunity, how will pricing offset the small patient population? - Management emphasized the importance of benefiting the patient population initially, with plans to expand the drug's use to other similar tumors once it is on the market [84][86] Question: Can you provide insights into the ADC program and its timing? - Management confirmed progress in identifying antibody targets and plans to provide a broader update later in the year [92] Question: Can you elaborate on the recent BMC Bioinformatics paper and its implications for the RADR platform? - Management highlighted that the paper validates the RADR platform's ability to make decisions about drug indications and genomic information [96][98] Question: Is there potential for the ATRT indication to qualify for a priority review voucher? - Management believes there is potential for ATRT to qualify for the priority review voucher program, which could add significant value [103]